Higher versus standard empagliflozin dose for metabolic syndrome
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests whether a higher dose of empagliflozin works better than the standard dose to treat metabolic syndrome. It may help improve blood sugar and cholesterol-related risk factors in people who meet the trial’s criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metabolic syndrome: central obesity (waist or BMI) plus 2 of 3 issues (high blood pressure, blood sugar problems, or high non-HDL cholesterol).
- You are not currently taking any SGLT2 inhibitor (including empagliflozin or similar diabetes/kidney medicines in that class).
- Your kidneys work well enough: eGFR is 30 or higher (not on dialysis).
- You have no severe liver problems and no known allergy to empagliflozin (Jardiance) or its ingredients.
- You are not pregnant, and you have not had ketoacidosis in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
This study tests two diabetes medications, empagliflozin and metformin, to see how they affect muscle energy use and blood flow in men with recently diagnosed type 2 diabetes. Participants will be followed at a diabetes clinic.
This study tests whether adding the diabetes pill empagliflozin (Jardiance) to your current automated insulin pump can help improve blood sugar control for adults with type 1 diabetes who are not reaching their glucose goals.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
Hear when a new Metabolic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.